What Is the Efficacy of Ixekizumab Across the GRAPPA and EULAR Domains?

Join Jessica Farrell, PharmD, Clinical Pharmacist at Albany Medical Center’s Division of Rheumatology and Professor at Albany College of Pharmacy and Health Sciences, as she examines the efficacy of Ixekizumab (Taltz) across key GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) domains in treating psoriatic arthritis (PsA) and psoriasis.

This discussion highlights how Ixekizumab performs across the diverse manifestations of PsA, including peripheral arthritis, axial disease, enthesitis, dactylitis, and both skin and nail psoriasis. Clinical data demonstrate its impact on ACR 20/50/70 scores, showing improvements in joint symptoms and axial disease response. Additionally, Ixekizumab has been proven effective in resolving enthesitis and dactylitis, reducing inflammation in tendons and digits. Patients with psoriasis also see significant improvements, with high rates of POSI 75/90/100 clearance and reductions in nail psoriasis severity, as measured by NAPSI scores.

Understanding Ixekizumab’s efficacy across GRAPPA domains is critical for healthcare providers selecting targeted therapies that address PsA’s multifaceted symptoms. This video explores how IL-17 inhibitors fit within GRAPPA treatment guidelines and how Ixekizumab can optimize patient care by delivering comprehensive disease control.

For more expert insights and the latest advancements in rheumatology, download the RhAPP ACE App for valuable resources and clinical updates.